There are currently 563 clinical trials in Gainesville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Florida /ID# 144834, University of Florida Health Science Center - Gainesville, University of Florida Shands Cancer Center and Sarkis Clinical Trials. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: SIMED Health, LLC, Gainesville, Florida
Conditions: Lung Cancer
Register for Updates
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
NCT04136002
Recruiting
The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population.
Gender:
All
Ages:
Between 45 years and 84 years
Trial Updated:
04/04/2023
Locations: University of Florida College of Medicine, Gainesville, Florida
Conditions: Colorectal Cancer
Register for Updates
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183
Recruiting
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Gender:
All
Ages:
All
Trial Updated:
03/23/2023
Locations: Clinical Trial Site, Gainesville, Florida
Conditions: Atypical Hemolytic-Uremic Syndrome
Register for Updates
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NCT04569435
Recruiting
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/23/2023
Locations: Annexon Investigational Site 02, Gainesville, Florida
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Airway Clearance for Pediatric and Adult Cystic Fibrosis Patients Using a Portable Intra-Pulmonary Percussion Device
NCT04743206
Recruiting
This is a pilot study where the investigators aim to compare initial use of the standard airway clearance device (SACD) with subsequent use of a Portable Intra-Pulmonary Percussion Device (PIAPD) in patients with cystic fibrosis ages 6 -21 years. The primary hypothesis is that there is no effect of PIAPD on FEV1 2 hours after use, there is no effect on perception of effort and efficacy for the PIAPD. If both are equally effective, the latter device provides an alternative that is both cheaper an... Read More
Gender:
All
Ages:
Between 6 years and 21 years
Trial Updated:
03/23/2023
Locations: UF Medical Plaza Pulmonary Clinic, Gainesville, Florida
Conditions: Cystic Fibrosis
Register for Updates
Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System
NCT01187368
Recruiting
This is a prospective, multi-center, unblinded, randomized, controlled, and non-inferiority study comparing the EVA2 LVAS to the most recent magnetically levitated centrifugal LVAS (HM3 LVAS).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2023
Locations: UF Health Shands Hospital, Gainesville, Florida
Conditions: Heart Failure
Register for Updates
Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients
NCT05442853
Recruiting
The investigators intend to conduct a single-center, prospective, randomized comparative trial of patients admitted to the intensive care unit (ICU) who received continuous glucose monitoring (CGM) vs point of care (POC) glucose monitoring. The study will examine relevant outcomes for patients in the ICU with diabetes mellitus and/or hyperglycemia. The primary outcome of the study will be the proportion of time in target range (blood glucose 70-180 mg/dL).
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
03/13/2023
Locations: North Florida/South Georgia Veterans Health System, Gainesville, Florida
Conditions: Hyperglycemia, Hypoglycemia, Critical Illness, Diabetes Mellitus
Register for Updates
SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects
NCT03669614
Recruiting
This is a Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of AR-501 (gallium citrate) solution, administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis (CF) subjects. Phase 1 of the study in HV subjects will consist of a single-ascending-dose (SAD) cohort, followed by the HV multiple-ascending-dose (MAD) cohort. Phase 2a of the study in CF subjects will consist of a MAD study design. The study will evaluate the safety and pharmaco... Read More
Gender:
All
Ages:
Between 18 years and 49 years
Trial Updated:
03/07/2023
Locations: Research Site, Gainesville, Florida
Conditions: Cystic Fibrosis
Register for Updates
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
NCT03363373
Recruiting
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Gender:
All
Ages:
1 year and above
Trial Updated:
03/06/2023
Locations: University of Florida, Gainesville, Florida
Conditions: Neuroblastoma
Register for Updates
Randomized Therapy In Status Epilepticus
NCT04391569
Recruiting
This study will evaluate the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
Gender:
All
Ages:
12 years and above
Trial Updated:
02/22/2023
Locations: Marinus Research Site, Gainesville, Florida
Conditions: Status Epilepticus
Register for Updates
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
NCT02464969
Recruiting
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
Gender:
All
Ages:
Between 0 days and 17 years
Trial Updated:
02/06/2023
Locations: UF Health Shands Hospital, Gainesville, Florida
Conditions: Venous Thromboembolism
Register for Updates
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
NCT05210283
Recruiting
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2023
Locations: University of Florida, Gainesville, Florida
Conditions: Colorectal Cancer
Register for Updates